PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules

Nephron

Volumn 129, Issue 1, 2015, Pages 68-74

  Fu, Yiling ^a,c   Gerasimova, Maria ^c   Batz, Falk ^a,c   Kuczkowski, Alexander ^a,c   Alam, Yasaman ^a,c   Sanders, Paul W ^d,e   Ronzaud, Caroline ^f   Hummler, Edith ^f   Vallon, Volker ^a,b,c,g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Body weight; Edema; Epithelial sodium channel; Kidney; Peroxisome proliferator activated receptor

Indexed keywords

ALDOSTERONE; ALPHA EPITHELIAL SODIUM CHANNEL; CREATININE; EPITHELIAL SODIUM CHANNEL; POTASSIUM ION; ROSIGLITAZONE; SODIUM ION; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCNN1A PROTEIN, MOUSE;

ADULT; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; FEMALE; FLUID INTAKE; FLUID RETENTION; FOOD INTAKE; HEMATOCRIT; KIDNEY COLLECTING TUBULE; KIDNEY CONNECTING TUBULE; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; SODIUM RETENTION; TOTAL BODY WATER; TREATMENT RESPONSE; AGONISTS; ANIMAL; BODY FLUID; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; EDEMA; GENE SILENCING; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; WEIGHT GAIN;

ANIMALS; BODY FLUIDS; DIET, SODIUM-RESTRICTED; EDEMA; EPITHELIAL SODIUM CHANNELS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, COLLECTING; MALE; MICE; MICE, KNOCKOUT; PPAR GAMMA; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 84930613282     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000370254     Document Type: Article

References (27)

1. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
2. Sharma AM, Staels B: Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92:386-395.
3. Nesto RW, Bell D, Bonow R.O., Fonseca V., Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich C.F., Smith S., Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108:2941-2948.
4. Vasudevan AR, Balasubramanyam A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6:850-863.
5. Niemeyer NV, Janney LM: Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22:924-929.
6. Sotiropoulos KB, Clermont A, Yasuda Y., Rask-Madsen C, Mastumoto M, Takahashi J., Della Vecchia K, Kondo T, Aiello LP, King GL: Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006; 20:1203-1205.
7. Emoto M, Anno T, Sato Y., Tanabe K, Okuya S, Tanizawa Y., Matsutani A, Oka Y: Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001; 50:1166-1170.
8. Gardiner SM, Nunez DJ, Baer P.G., Brown KK, Bennett T: Regional hemodynamic effects of the N-(2-benzoylphenyl)-L-tyrosine peroxisome proliferator-activated receptor-gamma ligand, GI 262570 [(S)-2-(2-benzoylphenyl amino)- 3-[4-[2-(5-methyl-2-phenyl-2-oxazol-4-yl)ethoxy]phenyl]propionic acid], in conscious rats. J Pharmacol Exp Ther 2004; 310:1226-1233.
9. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee T.R., Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134:61-71.
10. Chen L, Yang B, McNulty J.A., Clifton LG, Binz JG, Grimes AM, Strum J.C., Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK: GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 2005; 312:718-725.
11. Artunc F, Sandulache D, Nasir O., Boini KM, Friedrich B, Beier N, Dicks E., Potzsch S, Klingel K, Amann K, Blazer-Yost BL, Scholz W, Risler T, Kuhl D, Lang F: Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone. Pflugers Arch 2008; 456:425-436.
12. Vallon V, Hummler E, Rieg T., Pochynyuk O, Bugaj V, Schroth J., Dechenes G, Rossier B, Cunard R, Stockand J: Thiazolidinedioneinduced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 2009; 20:721-729.
13. Song J, Knepper MA, Hu X, Verbalis J.G., Ecelbarger CA: Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308: 426-433.
14. Zhang H, Zhang A, Kohan D.E., Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 2005; 102:9406-9411.
15. Guan Y, Hao C, Cha D.R., Rao R., Lu W, Kohan DE, Magnuson M.A., Redha R., Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861-866.
16. Viswanathan V, Mohan V, Subramani P., Parthasarathy N, Subramaniyam G, Manoharan D., Sundaramoorthy C, Gnudi L, Karalliedde J, Viberti G: Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clin J Am Soc Nephrol 2013; 8:225-232.
17. Rubera I, Loffing J, Palmer L.G., Frindt G., Fowler-Jaeger N, Sauter D, Carroll T., McMahon A, Hummler E, Rossier BC: Collecting duct-specific gene inactivation of alphaENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest 2003; 112:554-565.
18. Christensen BM, Perrier R, Wang Q., Zuber AM, Maillard M, Mordasini D, Malsure S., Ronzaud C, Stehle JC, Rossier BC, Hummler E: Sodium and potassium balance depends on alphaENaC expression in connecting tubule. J Am Soc Nephrol 2010; 21: 1942-1951.
19. Frindt G, Palmer LG: Na channels in the rat connecting tubule. Am J Physiol Renal Physiol 2004; 286:F669-F674
20. Meneton P, Loffing J, Warnock DG: Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol 2004; 287:F593-F601.
21. Masuda T, Fu Y, Eguchi A., Czogalla J, Rose MA, Kuczkowski A, Gerasimova M., Feldstein AE, Scadeng M, Vallon V: Dipeptidyl peptidase IV inhibitor lowers PPARgamma agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab 2014; 306:E388-E398.
22. Chapman ME, Hu L, Plato C.F., Kohan DE: Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am J Physiol Renal Physiol 2010; 299:F280-F283.
23. Karalliedde J, Buckingham R, Starkie M., Lorand D, Stewart M, Viberti G: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17: 3482-3490.
24. Buchanan TA, Meehan WP, Jeng Y.Y., Yang D., Chan TM, Nadler JL, Scott S, Rude R.K., Hsueh WA: Blood pressure lowering by piogli-tazone. Evidence for a direct vascular effect. J Clin Invest 1995; 96:354-360.
25. Yang B, Clifton LG, McNulty J.A., Chen L., Brown KK, Baer PG: Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats. J Cardiovasc Pharmacol 2003; 42:436-441.
26. Borsting E, Cheng VP, Glass C.K., Vallon V., Cunard R: Peroxisome proliferator-activated receptor-gamma agonists repress epithelial sodium channel expression in the kidney. Am J Physiol Renal Physiol 2012; 302:F540-F551.
27. Nofziger C, Chen L, Shane M.A., Smith CD, Brown KK, Blazer-Yost BL: PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel. Pflugers Arch 2005; 451: 445-453.